IP Library Granted Patent US 8,226,941
Granted Patent B2
US 8,226,941 · App. 11/568,831 · Granted Jul 24, 2012

Methods of purifying chondroitinase and stable formulations thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,226,941
App. No.
11/568,831
Granted
Jul 24, 2012
Kind
B2
Abstract

An aspect of the present invention relates to stable formulations of chondroitinase and to methods of purifying chondroitinase. The methods of purifying chondroitinase includes the steps of extracting the enzyme from a cell, separating the chondroitinase from the crude cell extract using cation-exchange chromatography, removing impurities through gel filtration chromatography, and removing endotoxin through an anion-exchange membrane to produce a purified chondroitinase.

Claims (17)

1. A stable formulation comprising a chondroitinase and a sodium phosphate buffer at a concentration of about 750-1000 mM, wherein the chondroitinase retains at least 50% of activity at about 24 hours.

2. The formulation of claim 1 , wherein said chondroitinase is purified.

3. The formulation of claim 1 wherein said chondroitinase is selected from the group consisting of chondroitinase ABCI, chondroitinase ABCII, chondroitinase AC, chondroitinase B mammalian enzymes with chondroitinase-like activity, Hyal1, Hyal2, Hyal3, Hyal4 and PH20.

4. The formulation of claim 1 , wherein said chondroitinase is chondroitinase ABCI.

5. The formulation of claim 1 , wherein said chondroitinase is chondroitinase AC.

6. The formulation of claim 1 further comprising sodium acetate.

7. The formulation of claim 1 , wherein said formulation is at a pH of about 7.4.

8. The formulation of claim 3 , wherein the chondroitinase ABC I is an amino acid sequence of SEQ ID NO: 2.

9. The formulation of claim 1 , wherein the sodium phosphate buffer concentration is about 750 mM.

10. The formulation of claim 1 , wherein the sodium phosphate buffer concentration is about 1000 mM.

11. The formulation of claim 1 , wherein said chondroitinase is chondroitinase ABCII.

12. The formulation of claim 1 , wherein said chondroitinase is chondroitinase B.

13. The formulation of claim 1 , wherein said chondroitinase is chondroitinase Hyal1.

14. The formulation of claim 1 , wherein said chondroitinase is chondroitinase Hyal2.

15. The formulation of claim 1 , wherein said chondroitinase is chondroitinase Hyal3.

16. The formulation of claim 1 , wherein said chondroitinase is chondroitinase Hyal4.

17. The formulation of claim 1 , wherein said chondroitinase is chondroitinase PH20.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2007
From: CAGGIANO, ANTHONY O.; GRUSKIN, ELLIOTT A.; SHEPTOVITSKY, YELENA G.; KASPERBAUER, SARAH
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 019208/0110 →